# Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

> **NCT06288113** · PHASE2 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **OTHER:** Gallium Ga 68 Gozetotide
- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Single Photon Emission Computed Tomography

## Key facts

- **NCT ID:** NCT06288113
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2027-01-27
- **Final completion:** 2028-01-27
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06288113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06288113, "Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06288113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*